Citations

Clear

146 citation(s) found for "Simpson, M".

Emerging approaches in neurostimulation for epilepsy
Osman, Gamaleldin , Starnes, Keith , Gregg, Nicholas M. , Osman, Gamaleldin M, Gregg, Nicholas M , Starnes, Donnie Keith , Lundstrom, Brian N. , Simpson, Hugh D.

Mayo Clinic

Current Opinion in Neurology | February 10, 2023 | Volume: 36 | Issue: 2 | Pages: 69-76

10.1097/wco.0000000000001138 | PMID 36762660 Get It

Purpose of review Neurostimulation is a quickly growing treatment approach for epilepsy patients. We summarize recent approaches to provide a perspective on the future of neurostimulation. Recent findings Invasive stimulation for treatment of focal epilepsy includes vagus nerve stimulation, responsive neurostimulation of the cortex and deep brain stimulation of the anterior nucleus of the thalamus. A wide range of other targets have been considered, including centromedian, central lateral and pulvinar thalamic nuclei; medial septum, nucleus accumbens, subthalamic nucleus, cerebellum, fornicodorsocommissure and piriform cortex. Stimulation for generalized onset seizures and mixed epilepsies as well as increased efforts focusing on paediatric populations have emerged. Hardware with more permanently implanted lead options and sensing capabilities is emerging. A wider variety of programming approaches than typically used may improve patient outcomes. Finally, noninvasive brain stimulation with its favourable risk profile offers the potential to treat increasingly diverse epilepsy patients. Summary Neurostimulation for the treatment of epilepsy is surprisingly varied. Flexibility and reversibility of neurostimulation allows for rapid innovation. There remains a continued need for excitability biomarkers to guide treatment and innovation. Neurostimulation, a part of bioelectronic medicine, offers distinctive benefits as well as unique challenges.
Clonal Kinetics and Single-Cell Transcriptional Profiles of T Cells Mobilized to Blood by Acute Exercise
Baker, Forrest L. , Smith, Kyle A. , Batatinha, Helena , Lau, Branden, Burgess, Shane C. , Gustafson, Michael P. , Zúñiga, Tiffany M. , Katsanis, Emmanuel , Simpson, Richard J.

Mayo Clinic

Medicine & Science in Sports & Exercise | January 31, 2023 | Volume: 55 | Issue: 6 | Pages: 991-1002

10.1249/mss.0000000000003130 | PMID 36719647 Get It

ABSTRACT Purpose Acute exercise redistributes large numbers of memory T cells, which may contribute to enhanced immune surveillance in regular exercisers. It is not known, however, if acute exercise promotes a broad or oligoclonal T-cell receptor (TCR) repertoire or evokes transcriptomic changes in “exercise-responsive” T-cell clones. Methods Healthy volunteers completed a graded bout of cycling exercise up to 80% V̇O 2max . DNA was extracted from peripheral blood mononuclear cells collected at rest, during exercise (EX), and 1 h after (+1H) exercise, and processed for deep TCR-β chain sequencing and tandem single-cell RNA sequencing. Results The number of unique clones and unique rearrangements was decreased at EX compared with rest ( P < 0.01) and +1H ( P < 0.01). Productive clonality was increased compared with rest ( P < 0.05) and +1H ( P < 0.05), whereas Shannon’s Index was decreased compared with rest ( P < 0.05) and +1H ( P < 0.05). The top 10 rearrangements in the repertoire were increased at EX compared with rest ( P < 0.05) and +1H ( P < 0.05). Cross-referencing TCR-β sequences with a public database (VDJdb) revealed that exercise increased the number of clones specific for the most prevalent motifs, including Epstein–Barr virus, cytomegalovirus, and influenza A. We identified 633 unique exercise-responsive T-cell clones that were mobilized and/or egressed in response to exercise. Among these clones, there was an upregulation in genes related to cell death, cytotoxicity, and activation ( P < 0.05). Conclusions Acute exercise promotes an oligoclonal T-cell repertoire by preferentially mobilizing the most dominant clones, several of which are specific to known viral antigens and display differentially expressed genes indicative of cytotoxicity, activation, and apoptosis.
Promoting validation and cross-phylogenetic integration in model organism research
Cheng, Keith C. , Burdine, Rebecca D. , Dickinson, Mary E. , Lloyd, K. C. Kent , MacRae, Calum A. , Morrison, John H., O’Connor, David H. , Rogers, Crystal D. , Sánchez, Susan , Simpson, J. , Talbot, William S. , Wallace, Douglas C. , Bellen, Hugo J , O'Connor, David H , Ekker, Stephen C. , Lin, Alex Y. , Lutz, Cathleen M. , Postlethwait, John H. , Weimer, Jill M. , Bellen, Hugo J.

Mayo Clinic

Disease Models & Mechanisms | September 20, 2022 | Volume: 15 | Issue: 9 | Pages: No page available

10.1242/dmm.049600 | PMID 36125045 Get It

ABSTRACT Model organism (MO) research provides a basic understanding of biology and disease due to the evolutionary conservation of the molecular and cellular language of life. MOs have been used to identify and understand the function of orthologous genes, proteins, cells and tissues involved in biological processes, to develop and evaluate techniques and methods, and to perform whole-organism-based chemical screens to test drug efficacy and toxicity. However, a growing richness of datasets and the rising power of computation raise an important question: How do we maximize the value of MOs? In-depth discussions in over 50 virtual presentations organized by the National Institutes of Health across more than 10 weeks yielded important suggestions for improving the rigor, validation, reproducibility and translatability of MO research. The effort clarified challenges and opportunities for developing and integrating tools and resources. Maintenance of critical existing infrastructure and the implementation of suggested improvements will play important roles in maintaining productivity and facilitating the validation of animal models of human biology and disease.
Practical considerations in epilepsy neurostimulation
Simpson, Hugh D. , Schulze‐Bonhage, Andreas , Cascino, Gregory D. , Fisher, Robert S. , Jobst, Barbara C. , Sperling, Michael R. , Lundstrom, Brian N. , Schulze-Bonhage, Andreas , Sperling, Michael R , Lundstrom, Brian Nils , Fisher, Robert , Jobst, Barbara

Mayo Clinic

Epilepsia | June 14, 2022 | Volume: 63 | Issue: 10 | Pages: 2445-2460

10.1111/epi.17329 | PMID 35700144 Get It

Abstract Neuromodulation is a key therapeutic tool for clinicians managing patients with drug‐resistant epilepsy. Multiple devices are available with long‐term follow‐up and real‐world experience. The aim of this review is to give a practical summary of available neuromodulation techniques to guide the selection of modalities, focusing on patient selection for devices, common approaches and techniques for initiation of programming, and outpatient management issues. Vagus nerve stimulation (VNS), deep brain stimulation of the anterior nucleus of the thalamus (DBS‐ANT), and responsive neurostimulation (RNS) are all supported by randomized controlled trials that show safety and a significant impact on seizure reduction, as well as a suggestion of reduction in the risk of sudden unexplained death in epilepsy (SUDEP). Significant seizure reductions are observed after 3 months for DBS, RNS, and VNS in randomized controlled trials, and efficacy appears to improve with time out to 7 to 10 years of follow‐up for all modalities, albeit in uncontrolled follow‐up or retrospective studies. A significant number of patients experience seizure‐free intervals of 6 months or more with all three modalities. Number and location of epileptogenic foci are important factors affecting efficacy, and together with comorbidities such as severe mood or sleep disorders, may influence the choice of modality. Programming has evolved—DBS is typically initiated at lower current/voltage than used in the pivotal trial, whereas target charge density is lower with RNS, however generalizable optimal parameters are yet to be defined. Noninvasive brain stimulation is an emerging stimulation modality, although it is currently not used widely. In summary, clinical practice has evolved from those established in pivotal trials. Guidance is now available for clinicians who wish to expand their approach, and choice of neuromodulation technique may be tailored to individual patients based on their epilepsy characteristics, risk tolerance, and preferences.
Adjustable Intragastric Balloon Leads to Significant Improvement in Obesity-Related Lipidome and Fecal Microbiome Profiles: A Proof-of-Concept Study
Hussan, Hisham , Johnson, Stephen , Grainger, Elizabeth M. , Brooks, Jeffrey , Hinton, Alice , Simpson, Christina, Kashyap, Purna , Hussan, Hisham , Dayyeh, Barham K. Abu , Chen, Jun , Riedl, Kenneth M. , Simpson, Christina

Mayo Clinic

Clinical and Translational Gastroenterology | June 7, 2022 | Volume: 13 | Issue: 7 | Pages: e00508

10.14309/ctg.0000000000000508 | PMID 35905412 Get It

INTRODUCTION: Intragastric balloons (IGBs) are a safe and effective treatment for obesity. However, limited knowledge exists on the underlying biological changes with IGB placement. METHODS: This single-institution study was part of an adjustable IGB randomized controlled trial. Subjects with obesity were randomized in a 2 is to 1 ratio to 32 weeks of IGB with diet/exercise counseling (n = 8) vs counseling alone (controls, n = 4). Diet/exercise counseling was continued for 24 weeks post-IGB removal to assess weight maintenance. We used mass spectrometry for nontargeted plasma lipidomics analysis and 16S rRNA sequencing to profile the fecal microbiome. RESULTS: Subjects with IGBs lost 15.5% of their body weight at 32 weeks vs 2.59% for controls ( P < 0.05). Maintenance of a 10.5% weight loss occurred post-IGB explant. IGB placement, followed by weight maintenance, led to a −378.9 μM/L reduction in serum free fatty acids compared with pre-IGB (95% confidence interval: 612.9, −145.0). This reduction was mainly in saturated, mono, and omega-6 fatty acids when compared with pre-IGB. Polyunsaturated phosphatidylcholines also increased after IGB placement (difference of 27 μM/L; 95% confidence interval: 1.1, 52.8). Compared with controls, saturated and omega-6 free fatty acids (linoleic and arachidonic acids) were reduced after IGB placement. The fecal microbiota changed post-IGB placement and weight maintenance vs pre-IGB ( P < 0.05). Further analysis showed a possible trend toward reduced Firmicutes and increased Bacteroidetes post-IGB and counseling, a change that was not conclusively different from counseling alone. DISCUSSION: IGB treatment is associated with an altered fecal microbiome profile and may have a better effect on obesity-related lipidome than counseling alone.
Protein‐losing enteropathy recurrence after pediatric heart transplantation: Multicenter case series
Sagray, Ezequiel , Johnson, Jonathan N. , Schumacher, Kurt R. , West, Shawn C. , Lowery, Ray , Simpson, Kathleen E. , West, Shawn , Simpson, Kathleen , Schumacher, K R

Mayo Clinic

Pediatric Transplantation | April 22, 2022 | Volume: 26 | Issue: 5 | Pages: No page available

10.1111/petr.14295 | PMID 35451219 Get It

AbstractBackgroundProtein‐losing enteropathy (PLE) is a devastating complication of the Fontan circulation. Although orthotopic heart transplantation (HTx) typically results in resolution of PLE symptoms, isolated cases of PLE relapse have been described after HTx.MethodsPatients with Fontan‐related PLE who had undergone HTx at participating centers and experienced relapse of PLE during follow‐up were retrospectively identified. Available data related to pre‐ and post‐HTx characteristics and PLE events were collected.ResultsEight patients from four different centers were identified. Median time from Fontan procedure to the development of PLE was 8 years, and median age at HTx was 17 years (range 7.7–21). In all patients, PLE resolved at a median time of 1 month after HTx (0.3–5). PLE recurrences occurred at a median time of 7.5 months after HTx (2–132). Each occurrence was associated with one or more significant clinical events; most commonly cellular‐ or antibody‐mediated rejection; and less commonly graft dysfunction, infection, thrombosis, and posttransplant lymphoproliferative disease. PLE recurrences resolved after the successful treatment of the concomitant event, after a median time of 2 months in seven cases, while persisted and recurred in one patient in association with atypical mycobacterium infection and subsequent PTLD onset and relapses. Six patients were alive during follow‐up at a median time of 4 years (1.3–22.5) after HTx.ConclusionsThis is the largest series of PLE recurrence after HTx. All cases were associated with one or more concomitant and significant clinical events. PLE typically resolved after resolution of the inciting clinical event.
Abstract GS4-07: The Breast PreCancer Atlas DCIS genomic signatures define biology and correlate with clinical outcomes: An analysis of TBCRC 038 and RAHBT cohorts
King, Lorraine , Simpson, Lunden , Khan, Aziz , Harmon, Bryan, Gallagher, Kristalyn K. , Kilgore, Mark , Wei, Shi, King, Tari A. , McAuliffe, Priscilla F. , Nangia, Julie R. , Lee, Joanna , Storniolo, Anna Maria , Thompson, Alastair M. , Burns, Robyn, Veis, Deborah J. , DeSchryver, Katherine, Matusiak, Magdalena , Wang, Jason, Tappenden, Jen, Ding, Daisy Yi , Zhang, Dadong , Jiang, Shu , Straub, Cody, Srivastava, Sucheta, Tibshirani, Rob , Angelo, Robert Michael, Owzar, Kouros , Polyak, Kornelia, Hwang, E. Shelley, Strand, Siri H. , Rivero‐Gutiérrez, Belén , Houlahan, Kathleen E. , Seoane, José Antonio , Risom, Tyler , Vennam, Sujay , Hardman, Timothy, Couch, Fergus J. , DeMichele, Angela , Tseng, Jennifer F. , Gupta, Gaorav P , Zhu, Chunfang , Zhu, Shirley , Luo, Jingqin , Varma, Sushama , Curtis, Christina , Angelo, Robert Michael, Hall, Allison , Polyák, Kornélia , Maley, Carlo C. , Marks, Jeffrey R. , Colditz, Graham A. , West, Robert B.

Mayo Clinic

Cancer Research | March 8, 2022 | Volume: 82 | Issue: 4_Supplement | Pages: GS4-07-GS4-07

10.1158/1538-7445.sabcs21-gs4-07 Get It

Abstract Background. DCIS consists of a molecularly heterogeneous group of premalignant lesions, with variable risk of invasive progression. Understanding biomarkers for invasive progression could help individualize treatment recommendations based upon tumor biology. As part of the NCI Human Tumor Atlas Network (HTAN), we conducted comprehensive genomic analyses on two large DCIS case-control cohorts. Methods. We performed smart3-seq and low-pass whole genome sequencing on two independent, retrospective, longitudinally sampled DCIS case-control cohorts. TBCRC 038 was a multicenter cohort diagnosed with DCIS between 1998 and 2016 at one of the Translational Breast Cancer Research sites; the RAHBT (Resource of Archival Human Breast Tissue) cohort included women identified through the St. Louis Breast Tissue Repository, and the Women’s Health Repository diagnosed between 1997 and 2001. We studied the spectrum of molecular changes present and sought genomic predictors of subsequent ipsilateral breast events (iBEs: DCIS recurrence or invasive progression) in both DCIS epithelium and stroma in formalin fixed paraffin embedded tissue. We generated de novo tumor and stroma-centric subtypes for DCIS that represents fundamental transcriptomic organization. Copy number analysis was performed using low-pass DNA sequencing. Non-negative matrix factorization (NMF) was applied to the RNA expression of all coding genes to identify clusters. A negative-binomial regression model was used to identify differentially expressed genes. Results. We analyzed 677 DCIS samples from 481 patients with 7.1 years median follow-up. In TBCRC samples, we identified three clusters via NMF in TBCRC referred to as ER low, quiescent, and ER high. The ER-low cluster had significantly higher levels of ERBB2 and lower levels of ESR1 compared to quiescent and ER-high clusters. Quiescent cluster lesions were less proliferative and less metabolically active than ER high and ER low subtypes. These findings were replicated in the RAHBT cohort. Focusing on the stromal component of DCIS from laser capture microdissection in RAHBT samples, we identified four distinct DCIS-associated stromal clusters. A “normal-like” stromal cluster with ECM organization and PI3K-AKT signaling; a “collagen-rich” stromal cluster; a “desmoplastic” stromal cluster with high fibroblast and total myeloid abundance, mostly associated with macrophages and myeloid dendritic cells (mDC); and an “immune-dense” stromal cluster. Further, we compared differentially expressed genes in patients with or without subsequent iBEs within 5 years of diagnosis. Hypothesizing that the resulting 812 DE genes (DESeq2) represent multiple routes to subsequent iBEs, we leveraged NMF to identify paths to progression. In both TBCRC and RAHBT cohorts, poor outcome groups exhibited increased ER, MYC signaling, and oxidative phosphorylation, supporting that these pathways are important for DCIS recurrence and progression. Conclusion. Comprehensive genomic profiling in two independent DCIS cohorts with longitudinal outcomes shows distinct DCIS stromal expression patterns and immune cell composition. RNA expression profiles reveal underlying tumor biology that is associated with later iBEs in both cohorts. These studies provide new insight into DCIS biology and will guide the design of diagnostic strategies to prevent invasive progression. Citation Format: Siri H Strand, Belén Rivero-Gutiérrez, Kathleen E Houlahan, Jose A Seoane, Lorraine M King, Tyler Risom, Lunden Simpson, Sujay Vennam, Aziz Khan, Timothy Hardman, Bryan E Harmon, Fergus J Couch, Kristalyn Gallagher, Mark Kilgore, Shi Wei, Angela DeMichele, Tari King, Priscilla F McAuliffe, Julie Nangia, Joanna Lee, Jennifer Tseng, Anna Maria Storniolo, Alastair Thompson, Gaorav Gupta, Robyn Burns, Deborah J Veis, Katherine DeSchryver, Chunfang Zhu, Magdalena Matusiak, Jason Wang, Shirley X Zhu, Jen Tappenden, Daisy Yi Ding, Dadong Zhang, Jingqin Luo, Shu Jiang, Sushama Varma, Cody Straub, Sucheta Srivastava, Christina Curtis, Rob Tibshirani, Robert Michael Angelo, Allison Hall, Kouros Owzar, Kornelia Polyak, Carlo Maley, Jeffrey R Marks, Graham A Colditz, E Shelley Hwang, Robert B West. The Breast PreCancer Atlas DCIS genomic signatures define biology and correlate with clinical outcomes: An analysis of TBCRC 038 and RAHBT cohorts [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr GS4-07.
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021
Tur, Carmen , Otero‐Romero, Susana , Amato, Maria Pia , Derfuss, Tobias , Pauli, Franziska Di , Abboud, Hesham , Achiron, Anat , Casanova, Jean‐Laurent , Clifford, David B. , Fonderico, Mattia , Gouider, Riadh , Hacohen, Yael , Kappos, Ludwig , Ladeira, Filipa , Louapre, Céline , Magyari, Melinda , Papeix, Caroline , Piehl, Fredrik , Ruíz-Camps, Isabel , Selmaj, Krzysztof , Simpson, Steve , Sıva, Aksel , Vaknin‐Dembinsky, Adi , Weinshenker, Brian G. , Winkelmann, Alexander, Rodas, María Isabel Zuluaga , Tintoré, Mar , Amato, Maria Pia , Derfuss, Tobias , Abboud, Hesham , Achiron, Anat , Dobson, Ruth , Filippi, Massimo , Fitzgerald, Kathryn C , Fonderico, Mattia , Hellwig, Kerstin , Hemmer, Bernhard , Ladeira, Filipa , Lebrun‐Frénay, Christine , Magyari, Melinda , Oreja-Guevara, Celia , Pandit, Lekha , Papeix, Caroline , Portaccio, Emilio , Simpson-Yap, Steve , Siva, Aksel , Sormani, Maria P , Vukusic, Sandra , Wiendl, Heinz , Tintoré, Mar , Weinshenker, Brian G , Casanova, Jean Laurent , Hacohen, Yael , Dubessy, Anne‐Laure , Iacobaeus, Ellen , Mycko, Marcin P. , Bellinvia, Angelo , Boyко, Alexey , Farez, Mauricio , Filippi, Massimo , Mehling, Matthias , Oreja‐Guevara, Celia , Pandit, Lekha , Sørensen, Per Soelberg , Sormani, Maria Pia , Trojano, María , Wiendl, Heinz , Stankoff, Bruno

Mayo Clinic

Multiple Sclerosis Journal | February 24, 2022 | Volume: 28 | Issue: 9 | Pages: 1424-1456

10.1177/13524585211069068 | PMID 35196927 Get It

Over the recent years, the treatment of multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) has evolved very rapidly and a large number of disease-modifying treatments (DMTs) are now available. However, most DMTs are associated with adverse events, the most frequent of which being infections. Consideration of all DMT-associated risks facilitates development of risk mitigation strategies. An international focused workshop with expert-led discussions was sponsored by the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and was held in April 2021 to review our current knowledge about the risk of infections associated with the use of DMTs for people with MS and NMOSD and corresponding risk mitigation strategies. The workshop addressed DMT-associated infections in specific populations, such as children and pregnant women with MS, or people with MS who have other comorbidities or live in regions with an exceptionally high infection burden. Finally, we reviewed the topic of DMT-associated infectious risks in the context of the current SARS-CoV-2 pandemic. Herein, we summarize available evidence and identify gaps in knowledge which justify further research.
Improving Immunization Rates During the 2019 Measles Outbreak
Rosas, Steven , Simpson, Henry J. , Walker, James A. , Forster, Jeremy, Deyo-Svendsen, Mark , Evers, Kaylie, Rosas, Steven L , Martinez, Christopher, Deyo-Svendsen, Mark E , Martinez, Christopher, Phillips, Michael

Mayo Clinic

Journal of Primary Care & Community Health | February 11, 2022 | Volume: 13 | Issue: No issue available | Pages: No page available

10.1177/21501319211069271 | PMID 35144495 Get It

In 2019, there were multiple outbreaks of measles in the United States. In the context of the public awareness of these outbreaks, we performed an intervention with the intent to improve the rate of measles immunization in our pediatric population. Pediatric patients that were lacking adequate measles immunization were identified by electronic medical record (EMR) survey. Charts were reviewed and updated if records were found to be incomplete. Parents of the remaining children were sent a letter, personally signed by the child’s primary care provider, encouraging measles immunization. A measles fact sheet, produced by the United States Center for Disease Control, was also included with the letter. There were 44 patients in the study group whose parents received a letter and measles fact sheet. As a result, 5 of these children were brought in for a measles, mumps, and rubella (MMR) immunization. The 44 patients whose parents received a letter included 20 patients whose parents had previously expressed intent to not vaccinate their children as documented in the EMR. None of these children received an MMR immunization. Although small in scope, this project provides a glimpse into the importance of personal provider guidance to parents who are inclined to immunize their children. Unfortunately, it also demonstrated that provider advice did not change the opinions of parents who had already taken a stance against vaccination, even in the context of an urgent public health situation that had garnered widespread coverage in the lay press and social media.
Abemaciclib: The First FDA-Approved CDK4/6 Inhibitor for the Adjuvant Treatment of HR+ HER2− Early Breast Cancer
Raheem, Farah , Ofori, Henry , Simpson, Lacey , Shah, Vishal , Shah, Vishal

Mayo Clinic

Annals of Pharmacotherapy | February 9, 2022 | Volume: 56 | Issue: 11 | Pages: 1258-1266

10.1177/10600280211073322 | PMID 35135362 Get It

Objective: To review the new indication of cyclin-dependent kinase (CDK4/6) inhibitor abemaciclib for the adjuvant treatment of hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2−), axillary lymph node (LN) positive early breast cancer (EBC) at high risk of recurrence and a Ki-67 ≥20%. Data Sources: A literature search was performed through PubMed, ClinicalTrials.gov, and Food and Drug Administration (FDA) website (February 1, 2018, to December 23, 2021) to identify relevant information. Study Selection and Data Extraction: Human and animal studies related to pharmacology, pharmacokinetics, efficacy, and safety of abemaciclib were identified. Data Synthesis: Addition of abemaciclib to standard of care endocrine therapy (ET) for patients with high-risk clinicopathologic features and Ki-67 ≥20% demonstrated 30% reduction in the risk of developing invasive disease and distant recurrence. At 15.5 months, abemaciclib + ET demonstrated a significant improvement in invasive disease-free survival (IDFS) vs ET alone (hazard ratio [HR], 0.75; 95% confidence interval [CI], 0.60-0.93, P = 0.01). At 27 months, IDFS benefit was maintained (HR, 0.70; 95% CI, 0.59-0.82, P < 0.0001). Diarrhea occurred in more than 80% of patients in the abemaciclib arm. Relevance to Patient Care and Clinical Practice: This review describes the clinical applicability of adjuvant abemaciclib for patients with HR+, HER2− EBC at high risk for recurrence. Conclusion: Adjuvant abemaciclib significantly reduces the risk for early development of invasive disease and distant recurrence in patients with HR+, HER2− node positive EBC. Longer follow-up is needed to determine the impact of adjuvant abemaciclib on late disease recurrence and survival outcomes.